Development and validation of a decision support tool to select IMRT as radiotherapy treatment planning modality for patients with locoregionally advanced non-small cell lung cancers (NSCLC)-Reference-Cited by-同舟云学术

Development and validation of a decision support tool to select IMRT as radiotherapy treatment planning modality for patients with locoregionally advanced non-small cell lung cancers (NSCLC)

Published:2019-02 Issue:1094 Volume:92 Page:20180431
ISSN:0007-1285
Container-title:The British Journal of Radiology
language:en
Short-container-title:BJR

Author:

Shrimali Raj Kumar¹,Chakraborty Santam¹^ORCID,Bhattacharyya Tapesh¹,Mallick Indranil¹,Achari Rimpa Basu¹,Prasath Sriram¹,Arun B¹,Mahata Anurupa¹,Vidhya Shree M¹,Vishnupriya E¹,Chatterjee Sanjoy¹

Affiliation:

1. Department of Radiation Oncology, Tata Medical Center, Rajarhat, Kolkata, India

Publisher

British Institute of Radiology

Subject

Radiology Nuclear Medicine and imaging,General Medicine

Link

https://www.birpublications.org/doi/pdf/10.1259/bjr.20180431

Reference23 articles.

1. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study

2. A Population-Based Comparative Effectiveness Study of Radiation Therapy Techniques in Stage III Non-Small Cell Lung Cancer

3. Intensity-Modulated Radiotherapy, Not 3 Dimensional Conformal, Is the Preferred Technique for Treating Locally Advanced Disease With High-Dose Radiotherapy: The Argument Against

4. Routine Use of Intensity-Modulated Radiotherapy for Locally Advanced Non–Small-Cell Lung Cancer Is Neither Choosing Wisely Nor Personalized Medicine

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dosimetric comparison of four radiotherapy techniques for stage III non‑small cell lung cancer;Oncology Letters;2023-06-27

2. Survival Outcomes From Concurrent Chemoradiation for Lung Cancer in Indian Patients are Comparable With Reported UK Outcomes;Clinical Oncology;2019-04